Holen Sie sich die Stockscreener-App
312.78
3.68%
11.11
Handel nachbörslich:
312.78
Schlusskurs vom Vortag:
$301.67
Offen:
$303.87
24-Stunden-Volumen:
1.09M
Relative Volume:
0.97
Marktkapitalisierung:
$41.76B
Einnahmen:
$4.29B
Nettoeinkommen (Verlust:
$577.22M
KGV:
74.32
EPS:
4.2086
Netto-Cashflow:
$641.34M
1W Leistung:
+6.69%
1M Leistung:
+9.32%
6M Leistung:
-21.84%
1J Leistung:
-5.15%
1-Tages-Spanne:
$303.00
$317.17
1-Wochen-Bereich:
$290.37
$317.17
52-Wochen-Spanne:
$273.11
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Komodo Expands Strategic Partnership with Alnylam Pharmaceuticals, Inc. (ALNY) - Yahoo Finance
July 2026's Top Stocks Estimated To Be Trading Below Their Intrinsic Value - simplywall.st
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Expanding Its Enterprise-Wide AI Analytics Partnership - simplywall.st
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $370 to $527 - Moomoo
Canaccord reiterates Alnylam stock Buy rating after RNAi event By Investing.com - Investing.com Canada
Is Alnylam Pharmaceuticals (ALNY) Undervalued Following Its Expanded Komodo Health AI Partnership? - simplywall.st
ALNY Maintains Buy Rating -- Price Target Lowered by HC Wainwrig - GuruFocus
H.C. Wainwright cuts Alnylam stock price target to $470 on revenue estimates - Investing.com Canada
Barclays Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $527 - Moomoo
Number of shareholders of Alnylam Pharmaceuticals, Inc – BX:DUL - TradingView
Price to sales forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY - TradingView
Enterprise value to EBITDA forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY - TradingView
Alnylam Pharmaceuticals, Inc Actuals & Estimates (NASDAQ:ALNY) - TradingView
Alnylam Pharmaceuticals unveils 2030 targets, betting on AMVUTTRA and pipeline readouts - MSN
Biopharma bites: Ionis' rare disease deal, Vaxart's COVID-19 funding, Alnylam's AI embrace and more from Definium - FirstWord Pharma
Enterprise value to EBIT forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY - TradingView
ALNY Forecast — Price Target — Prediction for 2027 - TradingView
Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh - TradingView
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding DisordersSlideshow (NASDAQ:ALNY) 2026-06-25 - Seeking Alpha
Komodo Health Expands Strategic Partnership with Alnylam Pharmaceuticals to Scale Marmot Analytics Ai Platform - marketscreener.com
Alnylam Pharmaceuticals Inc RNAi Roundtable Webcast Transcript - GuruFocus
Price to earnings forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY - TradingView
Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform - Business Wire
Oppenheimer Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $500 - Moomoo
Alnylam Pharmaceuticals (ALNY) Short Interest & Short Float | Updated Jun 2026 $ALNY - MarketBeat
Why (ALNY) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Maintains Target Price $370 - Moomoo
AI-Driven RNAi Push and Nordic Expansion Might Change The Case For Investing In Alnylam (ALNY) - simplywall.st
Alnylam Pharmaceuticals, Inc. (ALNY) and GENESIS Pharma Expand Commercial Partnership - Insider Monkey
Alnylam Pharmaceuticals (ALNY), Inceptive Form $2B Partnership to Advance RNAi Drug Discovery - Yahoo Finance
Regeneron gets US, EU review for myasthenia gravis drug (REGN) - Seeking Alpha
Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today - Sahm
Dyne Therapeutics adds ex-Sage CEO Barry Greene to board - Stock Titan
Alnylam (ALNY) Expands Its RNAi Therapeutics Reach Into Four More Nordic Countries - Insider Monkey
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Passes the "Little Book" Test with Explosive Growth and Upward Momentum - ChartMill
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra? - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Investor Outlook: A Biotech Leader with 56.90% Upside Potential - DirectorsTalk Interviews
Alnylam Pharmaceuticals, Inc. (ALNY) Partners with Inceptive Nucleics to Accelerate Growth as A High-Growth Large-Cap Stock - Insider Monkey
ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY): A Decent Value Play with Strong Growth at a Discount to Peers - ChartMill
Alnylam Pharmaceuticals Inc (ALNY) Institutional Confidence - TradingKey
Alnylam Pharmaceuticals Inc (ALNY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alnylam Pharmaceuticals Inc (ALNY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alnylam Pharmaceuticals Inc (ALNY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alnylam Pharmaceuticals Inc - TradingKey
Does Alnylam’s Generative AI Pact With Inceptive Nucleics Redraw The R&D Bull Case For ALNY? - simplywall.st
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and Alnylam Pharma (ALNY) - The Globe and Mail
Alnylam expands Genesis Pharma collaboration in Europe - MSN
Alnylam Taps Generative AI And Nordic Expansion As Market Lags Targets - Yahoo Finance
Understanding Momentum Shifts in (ALNY) - Stock Traders Daily
Alnylam Pharmaceuticals stock hits 52-week low at $282.71 By Investing.com - Investing.com Nigeria
Alnylam Pharmaceuticals stock hits 52-week low at $282.71 - Investing.com
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| PYOTT DAVID E I | Director |
Jun 01 '26 |
Sale |
299.18 |
3,830 |
1,145,853 |
1,582 |
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):